JNCE - Jounce Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Jounce Therapeutics, Inc.

780 Memorial Drive
Cambridge, MA 02139
United States
857-259-3840
http://www.jouncetx.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees124

Key Executives

NameTitlePayExercisedYear Born
Dr. Richard MurrayPres, CEO & Director769.81kN/A1959
Ms. Kimberlee Cobleigh DrapkinCFO & Treasurer494.99kN/A1968
Dr. Elizabeth G. TréhuChief Medical Officer532.61kN/A1960
Dr. James P. AllisonFounderN/AN/AN/A
Dr. Thomas F. GajewskiFounderN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company offers vopratelimab, a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors, which is in Phase I/II clinical trial for the treatment of head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, gastric cancer, and other tumor types identified through its translational science platform. It is also developing JTX-4014, a monoclonal antibody that is in Phase I clinical trial for combination therapy; and JTX-8064, a monoclonal antibody that binds to leukocyte immunoglobulin like receptor B2 that is in the IND-enabling phase. The company has a master research and collaboration agreement with Celgene Corporation focused on developing and commercializing biologic immunotherapies. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Jounce Therapeutics, Inc.’s ISS Governance QualityScore as of April 1, 2019 is 8. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.